Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875176 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661478 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661377 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL101673 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL660625 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814356-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-11974996-B2 | Naloxegol oxalate and solid dispersion thereof | AUROBINDO PHARMA LTD (IN) | 2024-05-07 | — | — | US | disclosed |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2023-12-19 | — | — | US | disclosed |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| EP-3814356-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | Zhejiang Vimgreen Pharmaceuticals, Ltd (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-10865186-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2020-12-15 | — | — | US | disclosed |
| EP-3074379-B1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS INDIA PVT LTD (IN) | 2019-06-26 | — | — | EP | disclosed |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2018-12-20 | — | — | US | disclosed |
| US-10081602-B2 | Opioid agonists and uses thereof | NEKTAR THERAPEUTICS (US) | 2018-09-25 | — | — | US | disclosed |
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | NEKTAR THERAPEUTICS | 2017-09-07 | — | — | US | disclosed |
| US-20030060606-A1 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-03-27 | — | — | US | disclosed |
| WO-2003022210-A2 | PHARMACEUTICAL COMPOSITIONS OF DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022208-A2 | PHARMACEUTICAL COMPOSITIONS OF INSULIN DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022996-A2 | METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME | NOBEX CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| US-20030027995-A1 | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| US-20030027748-A1 | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | BIOCON LIMITED (IN) | 2003-02-06 | — | — | US | disclosed |
| WO-2002098452-A1 | MIXTURES OF GROWTH HORMONE DRUG-OLIGOMER CONJUGATES COMPROMISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098451-A1 | MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098446-A1 | MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002098232-A1 | MIXTURES OF INSULIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME | NOBEX CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253565-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | USP2 4290/4885TSHR 608/4885KDM4E 3977/4885 |
| US-11974996-B2 | Naloxegol oxalate and solid dispersion thereof | XDH, OPRL1, OPRK1 | USP2 1239/4885TSHR 4312/4885KDM4E 2653/4885 |
| US-20180362468-A1 | OPIOID AGONISTS AND USES THEREOF | OPRM1, OPRK1, OPRD1 | USP2 4290/4885TSHR 608/4885KDM4E 3977/4885 |
| US-20030027748-A1 | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | IAPP, SI, IDE | USP2 2083/4885TSHR 1412/4885KDM4E 4615/4885 |
| US-10865186-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | USP2 4290/4885TSHR 608/4885KDM4E 3977/4885 |
| US-20030027995-A1 | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | GHRHR, GHSR, GHITM | USP2 774/4885TSHR 43/4885KDM4E 4494/4885 |
| US-11845751-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
| US-20030060606-A1 | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same | CALCB, CALCR, CALCA | USP2 1847/4885TSHR 1403/4885KDM4E 4598/4885 |
| US-10081602-B2 | Opioid agonists and uses thereof | OPRM1, OPRK1, OPRD1 | USP2 4290/4885TSHR 608/4885KDM4E 3977/4885 |
| US-20210332055-A1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | USP2 3328/4885TSHR 63/4885KDM4E 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.